EMA Authorised: Aqumeldi (Enalapril (maleate)) — Proveca Pharma Limited

View source ↗

Summary

Aqumeldi, containing enalapril maleate, has been authorised by EMA for the treatment of heart failure; the marketing authorization holder is Proveca Pharma Limi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Aqumeldi (Enalapril maleate)

Snippet

Status: Authorised. Therapeutic area: Heart Failure. MAH: Proveca Pharma Limited. Decision date: 20/10/2025